To Evaluate the Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients: A Randomized, Double-Blinded, Dose-Exploration and Placebo-Controlled Study
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs SPH 3127 (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Shanghai Pharmaceuticals Holding
- 01 Nov 2019 Status changed from not yet recruiting to recruiting.
- 01 Nov 2019 Planned End Date changed from 31 Jan 2020 to 30 Jun 2020.
- 01 Nov 2019 Planned primary completion date changed from 1 Jun 2019 to 30 Jun 2020.